Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.
about
Diastolic function in anthracycline-treated children.Cardio-oncology: a new medical issue.Zebrafish heart failure models for the evaluation of chemical probes and drugsTranscriptome profiling of peripheral blood cells identifies potential biomarkers for doxorubicin cardiotoxicity in a rat modelChemotherapy-induced cardiotoxicity.Management of mucopolysaccharidosis type IH (Hurler's syndrome) presenting in infancy with severe dilated cardiomyopathy: a single institution's experience.Anticancer efficacy and absorption, distribution, metabolism, and toxicity studies of aspergiolide A in early drug developmentCardiac involvement of churg-strauss syndrome as a reversible cause of dilated cardiomyopathyNT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivorsSerial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.Clinical Application of the Heart Rate Deceleration Capacity Test to Predict Epirubicin-induced CardiotoxicityTroponin as a marker of myocardiac damage in drug-induced cardiotoxicity.Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.Early detection of cardiotoxicity by 2D and 3D deformation imaging in patients receiving chemotherapy.Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice.Doxorubicin-Induced Cardiac Toxicity Is Mediated by Lowering of Peroxisome Proliferator-Activated Receptor δ Expression in Rats.Late congestive heart failure after hematopoietic cell transplantationHematopoietic stem cell transplantation for systemic lupus erythematosus, the antiphospholipid syndrome and bullous skin diseases.Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan.Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapyBortezomib-induced Severe Congestive Heart Failure.Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury.Therapeutic applications of carbon nanotubes: opportunities and challenges.A Novel Danshensu Derivative Prevents Cardiac Dysfunction and Improves the Chemotherapeutic Efficacy of Doxorubicin in Breast Cancer Cells.Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.Decreased oxygen transfer capacity of erythrocytes as a cause of 5-fluorouracil related ischemia.Prevention and treatment of doxorubicin-induced cardiotoxicity by dexrazoxane and schisandrin B in rabbits.Probucol attenuates cyclophosphamide-induced oxidative apoptosis, p53 and Bax signal expression in rat cardiac tissues.Assessment of early-onset chronic progressive anthracycline cardiotoxicity in children: different response patterns of right and left ventricles.Evaluation of safety parameters and changes in serum concentration in liver transplant recipients treated with doxorubicin during the anhepatic period.Challenging historical perspectives of the 24-h chemotherapy day: Flexible chemotherapy dose-timing guidelines.Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children.Attenuation of cyclophosphamide-induced pulmonary toxicity in Swiss albino mice by naphthalimide-based organoselenium compound 2-(5-selenocyanatopentyl)-benzo[de]isoquinoline 1,3-dione.Case report and review of the literature: the utilisation of a ventricular assist device as bridge to recovery for anthracycline-induced ventricular dysfunction.Cytochrome P450 2J2, a new key enzyme in cyclophosphamide bioactivation and a potential biomarker for hematological malignancies.Assessment of Myocardial Function in Children before and after Autologous Peripheral Blood Stem Cell Transplantation.Left Ventricular Ejection Fraction and Left Ventricular End-Diastolic Volume in Patients With Diastolic DysfunctionProtective Effect of Kolaviron on Cyclophosphamide-Induced Cardiac Toxicity in Rats
P2860
Q30459180-8E150B41-B795-42B0-915B-F6728D6F2EC7Q30471284-590BC45D-C3D0-4048-A904-1A8A949DE96DQ30560369-42BDBF76-15BF-4E30-82A5-05423302499AQ33404672-F65CEB8E-EE30-44E9-ACEF-7DC8DF842385Q34258080-C743F416-E326-4387-BD0F-6D2F3C7D57D0Q34311268-CD255562-7600-43FD-B2C2-A8DD641EFDD1Q34394244-3EEA9F60-245D-45D0-AB86-87166EF93DE4Q35436406-4ADA79E7-BA64-41C9-9AC7-829356C14315Q35557142-5B9F486E-0711-4661-A434-86471E91975EQ35623306-FDB3305C-8ECC-4D6A-913D-52AFA50DDEA9Q36136774-29266492-8BF9-4B48-AD34-185AD6374A15Q36150546-02EEA1CE-430E-4DB9-87E1-499ADDB7DC6DQ36160947-AF5623C8-608A-48E4-9F76-55840EE15A0AQ36365075-FB02C4B9-BA3D-4007-97C0-C4708F17E647Q36610126-0233FA81-A23A-4DAC-A6E3-0B1BAE14AAA7Q36701970-B022546D-32C2-4F27-BFCC-0F049EDB6B24Q37117167-8B5EB6AD-D438-43D4-9796-5481B018BCD5Q37311073-03C09E41-474D-41B2-BDA7-83E9E86B0CD6Q37342407-EFC405F0-6180-4742-B6D9-822A015EC233Q37671456-17939129-1CE0-4BE6-B653-CE80DAF088C8Q37711394-CCBD6ADE-30E1-4252-99E4-A53428ED9C0AQ38166071-EA7CBCBA-A43D-46BB-8268-BF0AB988217CQ38203215-A58639D2-F423-4EA7-BBB2-55D034003A49Q38865730-1DADFE84-A60F-4BC5-B9D0-8F4752CB8ECEQ40505582-7B75E783-F9BD-46F8-A0F8-8CE8ADFC1B69Q42608298-44C2AD15-A018-45F2-BEAC-ABD49B8D4D6CQ42726091-E4CC4D56-194D-4F15-A04B-2DD829D28DB2Q42780791-EC7B3098-849C-4F65-9398-0C311BC4E7CBQ44264332-7331B3D4-DEE0-4BCA-894E-5E88A220E495Q44479745-84A56C86-3FE6-48D0-B817-61764790105DQ45160611-660FE31A-0FD9-4F01-83B8-4B04BEDA4388Q46328753-4DB13727-40CA-4EF8-B26A-0BF661949BB3Q46803380-606FCF33-C9C7-485C-979B-85947E949FCEQ47290040-E808B6C4-FB6D-4B30-ADFD-F83E3D7E2EE3Q48234194-51D18BCB-F8CD-4105-8075-B6E84BFBD0ACQ53797858-BF902CDC-52C1-4D28-934E-EB10FD462FA1Q57181561-EE37F68B-040B-4A52-A5C0-563D1A959C40Q57931690-89804E4A-EC5E-44DA-8C6C-C9A473F778B0
P2860
Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.
@ast
Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.
@en
Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.
@nl
type
label
Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.
@ast
Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.
@en
Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.
@nl
prefLabel
Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.
@ast
Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.
@en
Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.
@nl
P2860
P1476
Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.
@en
P2093
P2860
P304
P356
10.1016/S1388-9842(01)00201-X
P577
2002-06-01T00:00:00Z